Develops Ersodetug, a first-in-class insulin-receptor modulating antibody designed to treat congenital hyperinsulinism and tumor-related hyperinsulinism by preventing recurrent, dangerous hypoglycemia.

Empowers artists impacted by homelessness or disability through art commerce and corporate partnerships.

Revolutionizes drug discovery by compressing months-long synthesis timelines into days through AI-powered robotic chemistry.

Revolutionizes drug discovery by compressing months-long synthesis timelines into days through AI-powered robotic chemistry.

Acquired by Neogen, a cloud based software that helps users implement food safety systems that reduce risk and elevate compliance.

Acquired by Eli Lilly, targets SARM1 to halt neurodegeneration in ALS, MS, and neuropathy, massive underserved markets where no curative solutions currently exist.

Developed, EGEN, s a proprietary gene-editing and genome engineering platform to create human-compatible organs and cells from pigs, aiming to eliminate transplant waitlists and reduce the need for lifelong immunosuppression.

Advancing lymph-node-targeted mKRAS cancer vaccines to treat high-need pancreatic and colorectal tumors driven by mutations found in a quarter of solid cancers.

Unlocks disease-specific RNA splicing isoforms through their AI platform, SpliceCore, opening entirely new therapeutic modalities for oncology and neurodegeneration.

Developed a multi-cancer early detection test, capitalizing on the billion-dollar shift toward precision medicine of preventing, predicting and guiding personalized treatment.

Combines chemoproteomics, covalent chemistry and machine-learning to uncover druggable sites on previously “undruggable” proteins and develop precision small-molecule therapies.

Combines human brain models, scalable biology, and machine learning to decode neurological disease and discover novel therapeutics.

Juul develops and sells nicotine vapor devices designed as an alternative to traditional cigarettes.

Uses machine-learning, high-throughput automation, and synthetic biology to engineer next-generation therapeutic antibodies via its EVA™ platform.

Now part of Medidata Solutions, MC10 develops ultra-thin, flexible electronics that integrate with the body to improve quality of life.

Leverages its machine-learning AnchorOmics platform to develop small-molecule therapies for high-value cancer targets.

Develops small-molecule therapies that target cancer-specific metabolic pathways identified through its proprietary computational, genomic, and metabolomic platform.

Drugging the biochemical centre of life.

Develops precision medicines for neuropsychiatric and neurodegenerative diseases, targeting novel CNS mechanisms with best-in-class pharmacology and leveraging biological insights to identify the right patient populations.

Now in a licensing agreement with GSK, Ochre Bio uses AI-driven human-liver datasets and RNA therapeutics to develop precision medicines for chronic liver diseases.

Develops IV-administered, self-amplifying RNA therapeutics designed to kill tumor cells and activate multiple arms of the immune system for transformative cancer outcomes.

Creates precision-engineered, high-quality cannabis devices and products that elevate the consumer experience, backed by nearly two decades of innovation and a commitment to being Plastic Negative.

Uses a proprietary cell-free protein synthesis and assembly platform to discover small-molecule modulators of multi-protein complexes across infectious and degenerative diseases.

Industrializes drug discovery through high-throughput automation, massive biological datasets and AI-driven models to decode biology and discover first-in-class therapeutics for multiple disease areas.

Combines physics-based molecular simulation with deep learning to generate novel Protein Interaction Modulators for oncogenic and inflammatory diseases.

Leverages single-cell multi-omics, functional assays and machine-learning to discover and develop transformational medicines based on deep biological relationships.

Develops first-in-class protein and peptide therapies that reset, rather than suppress, the immune system to deliver durable remission across autoimmune and allergic diseases.

(Merged entity) Advances in-cell delivery of gene and protein therapeutics using engineered fusogen technology to treat diseases at their cellular origin.

Biophysics company that developed Targeted Plasmonic Therapy (TPT) using proprietary plasmonic nanoparticles combined with existing energy devices to treat acne and remove light-pigmented hair.

Dominates AI-powered machine vision for manufacturing, capturing the industrial automation supercycle across food, agriculture, and consumer goods.

Designs solar-powered atmospheric water generators that convert air and sunlight into clean drinking water for homes, schools and communities.

Focused on advancing medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through novel, highly selective small-molecule inhibitors of KIT

Develops automated live-cell imaging systems and analytics that generate high-resolution, reproducible, AI-ready datasets, transforming how scientists capture and interpret dynamic cell biology.

Develops targeted immunotherapies that modulate immunosuppressive cell populations and pathways to restore anti-tumor immunity or prevent autoimmune attack.

Develops next-generation multispecific cancer therapies by combining DNA-based super-resolution microscopy with T-cell engagers, bispecifics/multispecifics, ADCs and radiopharmaceuticals for enhanced selectivity.

Develops cancer therapies, primarily targeting gastric and pancreatic cancer with its lead candidate, TTX-030, an anti-CD39 antibody.

Develops next-generation FGFR-targeted precision medicines using a structural design platform that anticipates resistance mutations to accelerate oncology and genetic disease therapies.

Harnesses human genetic diversity from underrepresented populations worldwide across 20+ research partnerships to identify disease-driving genes using AI/ML, creating a pipeline of "impossible-to-find" therapeutics for fibrotic, kidney, and liver diseases.

Delivers an AI-enabled diagnostic collaboration platform that pairs board-certified radiologists with intelligent imaging workflows to accelerate and enhance medical image interpretation.

Designs "shape-shifting" cytokine drugs using PREDATOR platform that activate only in tumors, unleashing validated immune mechanisms while preventing toxic side effects in peripheral tissue.